To a layman Dabur and Zandu are companies operating in the niche ayurveda segment. At first glance these companies seem alike because of their 'ayurvedic' image. But probe a little further and you find two very different entities.
While Zandu Pharmaceuticals manufactures pharmaceutical preparations, Dabur India Limited is a 115 year old FMCG company operating in the niche natural/ayurvedic products segment with a product folio of over 500 products.
Both companies specialise in branded ayurvedic products such as Ghritas, Churna, and Chyawanprash, but Dabur's product portfolio is not only more expansive in terms of brands, it also has a wider retail reach.
A look at their FY2000 financial performance, further underlines this difference.
Net profit margin
While Dabur definitely outpaces Zandu in terms of size and margins, Zandu historically enjoys better valuations (EPS and P/E multiples). The discounting of Dabur vis-à-vis Zandu on the bourses seems to be a result Dabur's frequent entry into new areas and the diversified range of its business. However, the difference in their valuations has come down quite a bit since Dabur embarked on a restructuring exercise recommended by McKinsey & Co.
From the P/E performance over the years it is apparent that the bourses have taken note of the changes taking place at Dabur and are urging Zandu to pep up its act.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407